JGC
MTNB icon

J. Goldman & Co’s Matinas BioPharma MTNB Stock Holding History

J. Goldman & Co’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,900
Closed -$1.14M – 319
2019
Q1 		$1.14M Buy
+20,900
New +$1.13M 0.06% 193

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

J. Goldman & Co's MTNB Position: Q2 2019 in Review

J. Goldman & Co sold out of Matinas BioPharma (MTNB) in Q2 2019, closing a stake of 20,900 shares — an estimated $1.14M sold.

J. Goldman & Co first reported a position in MTNB in Q1 2019 and held it in 1 quarter. The position peaked at $1.14M in Q1 2019. 47 funds tracked by Wall St. Rank hold MTNB as of Q2 2019.

  • J. Goldman & Co reported no remaining Matinas BioPharma position as of Q2 2019 after selling out during the quarter.
  • J. Goldman & Co sold 20,900 Matinas BioPharma shares in Q2 2019, an estimated $1.14M.
  • J. Goldman & Co first reported a position in Matinas BioPharma in Q1 2019 and held it in 1 quarter.
  • J. Goldman & Co's Matinas BioPharma position peaked at $1.14M in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2019.

Based on J. Goldman & Co's 13F filing for Q2 2019, filed 14 Aug 2019.